Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intravitreal Topotecan for the Prevention or Treatment of Proliferative Vitreoretinopathy in Patients with Rhegmatogenous Retinal Detachment: a Prospective Matched Cohort Study

NCT06818721 is registered in ClinicalTrials.gov with Unity Health Toronto as lead sponsor.

NCT NCT06818721
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06818721 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intravitreal Topotecan for the Prevention or Treatment of Proliferative Vitreoretinopathy in Patients with Rhegmatogenous Retinal Detachment: a Prospective Matched Cohort Study
Lead sponsor
Unity Health Toronto
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 31, 2025
Completion date
April 30, 2027
Enrollment
394 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

proliferative vitreoretinopathy, retinal detachment rhegmatogenous